[
    {
        "id": 1,
        "image": "thumb_44_540_0_0_0_auto.png",
        "source": "https://www.hankyung.com/it/article/202212083036i",
        "title": "입셀·파이안바이오, 미토콘드리아 재생의료 치료제 개발 협약",
        "content": "",
        "dateTime": "Dec 08, 2022"
    },
    {
        "id": 2,
        "image": "thumb_43_540_0_0_0_auto.jpg",
        "source": "https://www.hankyung.com/it/article/202207122116i",
        "title": "파이안바이오 '미토콘드리아 치료제, 해외 제약사 2곳과 공동연구'",
        "content": "",
        "dateTime": "Jul 12, 2022"
    },
    {
        "id": 3,
        "image": "thumb_38_540_0_0_0_auto.jpg",
        "source": "https://www.donga.com/news/It/article/all/20220423/113035474/1?ref=main",
        "title": "미토콘드리아 치료제 세계 첫 임상… 면역세포 치료-항암제까지",
        "content": "",
        "dateTime": "Apr 23, 2022"
    },
    {
        "id": 4,
        "image": "thumb_37_540_0_0_0_auto.jpg",
        "source": "https://www.hankyung.com/it/article/202112071993i",
        "title": "파이안바이오 “미토콘드리아 유럽 임상 위한 CMO 계약 논의”",
        "content": "",
        "dateTime": "Dec 07, 2021"
    },
    {
        "id": 5,
        "image": "thumb_39_540_0_0_0_auto.jpg",
        "source": "https://www.hankyung.com/it/article/202110202008i",
        "title": "[유망기업] 미토콘드리아로 세계 첫 임상 나선 파이안바이오테크놀로지",
        "content": "",
        "dateTime": "Oct 25, 2021"
    },
    {
        "id": 6,
        "image": "thumb_36_540_0_0_0_auto.jpg",
        "source": "https://www.hankyung.com/it/article/202109065727i",
        "title": "파이안바이오 순천향대학교 중앙의료 원 및 순천향 의생명연구원과 미토콘드리아 치료제 공동 연구 개 발 을 위한 MOU 체결",
        "content": "",
        "dateTime": "Sep 06, 2021"
    },
    {
        "id": 7,
        "image": "thumb_35_540_0_0_0_auto.jpg",
        "source": "https://www.hankyung.com/it/article/202106179415i",
        "title": "파이안바이오, 미토콘드리아 치료제 국내 1·2a상 승인",
        "content": "",
        "dateTime": "Jun 17, 2021"
    },
    {
        "id": 8,
        "image": "thumb_30_540_0_0_0_auto.png",
        "source": "https://biz.chosun.com/stock/stock_general/2021/06/17/Y2ICBHE75RHZTN3XCFO3LXGUVE/",
        "title": "120억원 투자 받은 파이안바이오, 미토콘드리아 신약 임상 계획 승인",
        "content": "",
        "dateTime": "Jun 17, 2021"
    },
    {
        "id": 9,
        "image": "thumb_32_540_0_0_0_auto.png",
        "source": "",
        "title": "IND Approval for PN-101 by MFDS",
        "content": "<p>PAEAN Biotechnology, a company specializing in the development of new mitochondrial drugs, announced today that the Ministry of Food and Drug Safety (MFDS) has approved the Investigational New Drug (IND) application for its lead product, PN-101 the world’s first allogeneic mitochondrial drug candidate for the treatment of polymyositis and dermatomyositis. PN-101 is the first-in-class drug where the main component consists of mitochondria isolated from stem cells.</p><p>The approved trial design will be a prospective open, dose-escalation, single-center phase I/IIa trial to evaluate the safety, tolerability, and efficacy of PN-101 in patients. Clinical trials will be conducted at Seoul National University Hospital for up to 18 patients.</p><p>Polymyositis and dermatomyositis are categorized as rare diseases, where the approved treatments such as steroids, immunoglobulins, and steroid-sparing drugs (e.g., immunosuppressants and immunomodulators) have been used. Patients who do not receive the treatment due to side effects of steroids or immunosuppressants, or who do not respond to the steroids, urgently need a novel treatment.</p><p>Kyuboem Han, CEO of PAEAN Biotechnology mentioned, “With the approval of the PN-101 clinical trial by the MFDS we will accelerate the development of indications in future for the mitochondrial-related incurable diseases. We plan Series B funding in the second half of this year to secure the necessary clinical development costs and further development of other mitochondrial drug candidates”. In addition, he said, “We recently completed a brand new GMP facility for clinical trials in Seoul office. Using this GMP facility, we will focus on clinical trials and commercialization of mitochondrial drugs.”</p>",
        "dateTime": "Jun 16, 2021"
    },
    {
        "id": 10,
        "image": "thumb_33_540_0_0_0_auto.jpg",
        "source": "",
        "title": "Completion of Mitochondria GMP Facility",
        "content": "PAEAN has finished the construction of new Mitochondria GMP Facility.",
        "dateTime": "Jun 16, 2021"
    },
    {
        "id": 11,
        "image": "thumb_23_540_0_0_0_auto.jpg",
        "source": "https://vod.kbs.co.kr/index.html?source=episode&sname=vod&stype=vod&program_code=T2020-0336&amp",
        "title": "KBS 특별기획 코로나19 이후, 대한민국 길을 묻다",
        "content": "(주)파이안바이오테크놀로지 부분은 동영상 41-44분 참조",
        "dateTime": "Apr 23, 2022"
    },
    {
        "id": 12,
        "image": "thumb_29_540_0_0_0_auto.png",
        "source": "https://news.v.daum.net/v/20210421114012208?f=m",
        "title": "2021년 과학정보통신의 날 국가연구개발성과 평가부문에서 '과학기술 포장' 수상",
        "content": "(주)파이안바이오테크놀로지 김천형 수석부사장 과학기술포장 수상",
        "dateTime": "Apr 21, 2021"
    },
    {
        "id": 13,
        "image": "thumb_42_540_0_0_0_auto.jpg",
        "source": "https://n.news.naver.com/article/015/0004449839",
        "title": "파이안바이오 ”미토콘드리아 활용해 암 치료 시대 열 것”",
        "content": "",
        "dateTime": "Nov 15, 2020"
    },
    {
        "id": 14,
        "image": "thumb_41_540_0_0_0_auto.jpeg",
        "source": "https://www.hankyung.com/it/article/201908267113f",
        "title": "파이안바이오 ”미토콘드리아로 희귀질환·암 치료제 개발…내년 본격 임상”",
        "content": "",
        "dateTime": "Aug 26, 2019"
    },
    {
        "id": 15,
        "image": "thumb_40_540_0_0_0_auto.png",
        "source": "http://www.paxetv.com/news/articleView.html?idxno=75307",
        "title": "[현장중계] 바이오큐어팜·파이안 등 바이오기업 모였다...기술 경쟁 ‘치열’",
        "content": "",
        "dateTime": "Jun 28, 2019"
    },
    {
        "id": 16,
        "image": "thumb_19_540_0_0_0_auto.jpeg",
        "source": "http://m.biospectator.com/view/news_view.php?varAtcId=8243",
        "title": "Paean Bio Targets Autoimmune and Tumor with 'MT Transplant Platform'",
        "content": "",
        "dateTime": "May 15, 2019"
    }
]